Ask AI
Advances in Smoldering and NDMM

CE

Advances in Smoldering and Transplant-Eligible Newly Diagnosed Multiple Myeloma: Risk Stratification, MRD-Guided Therapy, and Emerging Treatment Strategies

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802-1824.
  2. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086-1107.
  3. Vaxman J, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828-838.
  4. Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.
  5. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127-1136.
  6. Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126-1137.
  7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. v.5.2026. nccn.org. Accessed July 16, 2026.
  8. Dimopoulos MA, Voorhees PM, Schjesvold F, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392:1777-1788.
  9. Siegel. CA Cancer J Clin. 2026;76:e70043.
  10. Surveillance, Epidemiology, and End Results (SEER) Program. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program. https://seer.cancer.gov/. Accessed July 27, 2026.
  11. Parikh RH, Hofmeister CC, Almaula D, et al. Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach. Journal of Clinical Oncology. 2022;40(16_suppl):8061. doi:10.1200/JCO.2022.40.16_suppl.8061.
  12. Joseph NS, Kaufman JL, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928-1937.
  13. Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739-2751.
  14. Hauwel M, Matthes T. Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies? Swiss Med Wkly. 2014;144:w13907.
  15. Neumeister P, Schulz E, Pansy K, et al. Targeting the microenvironment for treating multiple myeloma. Int J Mol Sci. 2022;23:7627.
  16. van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13-29.
  17. Costa F, Dalla Palma B, Giuliani N. CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents. Cells. 2019;8:1632.
  18. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132-147.
  19. Voorhees PM, Sborov DW, Laubach JP, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825-e837.
  20. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2023;390:301-313.
  21. Gay F, Roeloffzen W, Dimopoulos MA, et al. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. Nat Med. 2026;32:1773-1782.
  22. Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol. 2025;43:1279-1288.
  23. Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35:2900-2910.
  24. Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42:26-37.
  25. Perrot A, Lambert J, Hulin C, et al. Measurable residual disease–guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393:425-437.
  26. Badros A, Foster L, Anderson, Jr LD, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145:300-310.